Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
pharmaceutical investing Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
Maritime Resources: A Low-risk Path to Gold Production in One of the World’s Top Mining Jurisdictions
